Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study

Abstract During the COVID-19 pandemic our center adjusted the standard induction therapy for normal immunological risk simultaneous pancreas-kidney (SPK) transplantations from T-cell depletion by alemtuzumab (ALEM) to IL-2 receptor blocking by basiliximab (IL2R). Here, we analyze the impact of this...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Tim D. A. Swaab, Robert A. Pol, Meindert J. Crop, Jan-Stephan F. Sanders, Stefan P. Berger, Hendrik S. Hofker, Stephan J. L. Bakker, Charlotte A. te Velde-Keyzer
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Nature Portfolio 2025-07-01
Schriftenreihe:	Scientific Reports
Schlagworte:	Pancreas transplantation Immunosuppression Induction Alemtuzumab Basiliximab COVID-19
Online-Zugang:	https://doi.org/10.1038/s41598-025-06750-y
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!